DMO study shows robust efficacy of intravitreal dexamethasone implant

Ophthalmology Times EuropeOphthalmology Times Europe May 2021
Volume 17
Issue 4

In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.

picture of syringe

A retrospective study including patients with at least 12 months of follow-up care shows that the intravitreal dexamethasone 0.7-mg implant Ozurdex (Allergan) provides safe and durably effective treatment for diabetic macular oedema (DMO) across the spectrum of patients who are seen by physicians in routine clinical practice. Although the research found that treatment-naïve patients generally had greater benefit than those who had a history of having received anti-vascular endothelial growth factor (VEGF) treatments, it also showed that eyes with long-standing, chronic DMO responded to the sustained-release steroid treatment.

In addition, the analyses showed that effectiveness was not related to reinjection interval. “Although evidence from clinical trials shows the safety and efficacy of the dexamethasone implant for treating DMO, it is important to collect data from real-world settings,” said Dr Albert J. Augustin, professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany, and lead author of the study.

Dr Augustin noted that the results of the study are consistent with prior studies and support the utility of the dexamethasone implant as a treatment for DMO in routine practice. “However, the results are preliminary and further, larger-scale studies are warranted,” he pointed out.

The study identified 141 patients treated at seven hospital-based medical retina centres in Germany (n = 108) and Switzerland (n = 33). Eligible patients had DMO-related visual impairment and at least 12 months of follow-up after the first implant injection. For each patient, data from a single eye was analysed – either the eye that received the most injections or one chosen by the investigator if injection number was the same for both eyes.

Baseline data

The baseline data showed that compared with the Swiss cohort, patients from Germany had a longer history of DMO (106 vs 31 months) and included a greater percentage of anti-VEGF treatment-naïve patients (40.7% vs 3.0%). In addition, considering the subgroup of patients who had received anti-VEGF injections, the mean number of injections was two-fold higher in the German cohort compared with the Swiss patients (63 vs 31). At baseline, the mean best corrected visual acuity (BCVA) for the study eyes was 61.6 letters and mean central retinal thickness (CRT) was 413.3 μm.

According to investigators, changes from baseline to 7 to 12 weeks post injection for both BCVA and CRT were analysed as efficacy end points. Across the entire cohort, the mean number of reinjections was three (range, 1-11) and they were given at a mean interval of 5.7 months (median, 4.6 months). BCVA was relatively stable after each reinjection with a mean change from baseline BCVA of +3.4, +3.7, +3.2 and –1.4 letters at 7 to 12 weeks after the first injection and reinjections one, two and three, respectively.

Greater benefit

Relatively greater benefit was seen in the analyses of CRT with changes from baseline of –88.3, –81.6, –102.4, and –124.1 μm at 7 to 12 weeks after the first injection and reinjections one, two and three, respectively. Dr Augustin explained that it is well known that CRT does not necessarily correspond with visual acuity. “In some patients, an increase in visual acuity follows the CRT improvement,” he said. “However, in other patients, it is necessary to evaluate the retinal structure in more detail to understand the phenomenon.”

Dr Augustin noted that this is why investigators have to look at other optical coherence tomography (OCT) results, such as retinal structure, external limiting membrane, ellipsoid zone, etc. “EURETINA [the European Society of Retina Specialists] has published a guideline focusing on such OCT results that helps us to better predict the result of intravitreal treatments in patients with DMO,” he added.

Treatment-naïve vs previously treated

Patients receiving the intravitreal implant as their first treatment for DMO had worse BCVA at baseline than their previously treated counterparts (mean, 57.8 vs 63.4 letters) and “more” DMO (mean CRT, 439.1 vs 400.6 μm). Compared with the patients who had a history of anti-VEGF treatment, the treatment-naïve patients had greater functional improvement, but less change in CRT.

Dr Augustin noted that the mean change in BCVA from baseline after the first injection in the treatment-naïve and previously treated patients was +4.7 vs +3.0 letters, respectively, and was +4.2 vs +3.5 letters, respectively, after the first reinjection. Mean CRT change from baseline in the treatment-naïve and previously treated patients was -74.3 vs -63.8 μm, respectively, after the first injection and -63.8 vs -85.8 μm, respectively. The Spearman correlation coefficient showed there was no statistically significant correlation between reinjection interval and either change from baseline in BCVA or CRT for the overall population or in analyses performed for each country individually, Dr Augustin reported.


Dr Augustin concluded with: “Although there was not a significant correlation between reinjection interval and change from BCVA, the small loss in BCVA that was seen after the third reinjection may be due to the reinjection interval.” Moreover, he noted that treatment with the dexamethasone implant had a favourable safety profile in patients.

Only 18% of patients experienced at least one adverse event, with ocular hypertension being the most common. There was no increase in number of adverse events with increasing number of injections.


Albert J. Augustin, MD
This article is based on Dr Augustin’s presentation at the EURETINA 2020 virtual meeting. Dr Augustin has received research support and consulting/advisory fees from Allergan and other companies that market products used for the treatment of DMO.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.